Biocon Biologics has been recognized as an Asia IP Elite for 2025 by IAM (Intellectual Asset Management), a leading Intellectual Property publication. This marks the ninth consecutive year that Biocon and Biocon Biologics have appeared on this list. The recognition highlights the company’s commitment to innovation and strong intellectual property strategy, reinforcing its stature as a global biosimilars leader.
IP Elite Recognition
Biocon Biologics Limited, a subsidiary of Biocon Ltd., has been recognized as an Asia IP Elite for 2025 by IAM (Intellectual Asset Management). This award was presented during IPBC Asia, held in Tokyo from November 18–20, 2025.
Consistent IP Value Creation
Biocon first appeared on the Asia IP Elite list in 2016, becoming the first Indian pharmaceutical company to be featured for its IP management and value creation. The 2025 recognition marks the ninth consecutive year Biocon and Biocon Biologics have been on this list.
Commitment to Innovation
Shreehas Tambe, CEO & Managing Director, Biocon Biologics, stated that this recognition reflects the company’s sustained commitment to innovation and a strong IP strategy. It reinforces Biocon Biologics’ growing stature as a global biosimilars leader and its role in expanding access to affordable therapies.
About IAM
IAM (Intellectual Asset Management) provides insight and expertise on managing intellectual property as a key business asset. Its tools and intelligence empower companies to mitigate risks and maximize the value of patent, trade secret and other IP assets.
About Biocon Biologics
Biocon Biologics is dedicated to transforming healthcare and lives, serving over 6.3 million patients across 120+ countries. The company has commercialized 10 biosimilars and has a pipeline of 20 biosimilar assets.
Source: BSE